Literature DB >> 29443381

Guillain-Barré-like syndrome during pembrolizumab treatment.

Stephanie Ong1, James Chapman1, Gavin Young1, Talal Mansy1.   

Abstract

Entities:  

Keywords:  Guillain-Barré syndrome; PD-1 inhibitor; immune checkpoint inhibitor; immune-related adverse event; pembrolizumab

Year:  2018        PMID： 29443381     DOI： 10.1002/mus.26101

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  4 in total

Review 1.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

2.  Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature.

Authors:  Bogna N Brzezinska; Robert V Higgins; Bunja Rungruang
Journal:  Gynecol Oncol Rep       Date:  2021-03-02

3.  Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.

Authors:  Nicholas Gravbrot; Katalin Scherer; Srinath Sundararajan
Journal:  Case Rep Oncol Med       Date:  2019-11-22

Review 4.  Immune Checkpoint Inhibitors and Neurotoxicity.

Authors:  Zhiyi Zhao; Chunlin Zhang; Lian Zhou; Pan Dong; Lei Shi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.